Pharmacological treatment of unipolar depression during pregnancy and breast-feedingA clinical overview

Nordic Journal of Psychiatry

Volumn 66, Issue 3, 2012, Pages 159-166

  Nielsen, René Ernst ^a   Damkier, Per ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Abnormalities; Antidepressive agents; Breast feeding; Depression; Pregnancy

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESVENLAFAXINE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

BIRTH DEFECT; BIRTH WEIGHT; BREAST FEEDING; CARDIOVASCULAR MALFORMATION; CONGENITAL HYPOTHYROIDISM; CONGENITAL MALFORMATION; DEHYDRATION; DIABETES INSIPIDUS; DISEASE ASSOCIATION; DRUG MONITORING; DRUG SAFETY; EBSTEIN ANOMALY; ELECTROCONVULSIVE THERAPY; FIRST TRIMESTER PREGNANCY; HEART SEPTUM DEFECT; HUMAN; INFANTILE HYPOTONIA; IRRITABILITY; IRRITABILITY SYNDROME; LARGE FOR GESTATIONAL AGE; LOW BIRTH WEIGHT; MAJOR DEPRESSION; NAUSEA AND VOMITING; NEWBORN DISEASE; NEWBORN PRIMARY PULMONARY HYPERTENSION; ORTHOSTATIC HYPOTENSION; PREGNANCY; PREMATURE LABOR; PREMATURITY; PRENATAL ANTIDEPRESSANT EXPOSURE SYNDROME; PRENATAL DRUG EXPOSURE; PSYCHOPHARMACOTHERAPY; PULMONARY ASPIRATION; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SIDE EFFECT; SMALL FOR DATE INFANT; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; URINE RETENTION; UTERUS CONTRACTION;

ADULT; ANTIDEPRESSIVE AGENTS; BREAST FEEDING; DEPRESSIVE DISORDER; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; LACTATION; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84861997051     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2011.650198     Document Type: Review

References (94)

1. Ketter TA, Citrome L, Wang PW, Culver JL, Srivastava S. Treatments for bipolar disorder: Can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand 2011;123:175-89.
2. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: A systematic review of prevalence and incidence. Obstet Gynecol 2005;106:1071-83. (Pubitemid 41532916)
3. Beck CT. Postpartum depression: It isn ' t just the blues. Am JNurs 2006;106:40-50. (Pubitemid 43772363)
4. Reulbach U, Bleich S, Knorr J, Burger P, Fasching PA, Kornhuber J, et al. [Pre-, peri- and postpartal depression]. Fortschr Neurol Psychiatr 2009;77:708-13.
5. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499-507. (Pubitemid 43200344)
6. Gentile S. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects. Acta Psychiatr Scand 2011;123:266-75.
7. Gentile S, Bellantuono C. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: Focus on paroxetine. J Clin Psychiatry 2009;70: 414-22.
8. Bennett IM, Marcus SC, Palmer SC, Coyne JC. Pregnancy-related discontinuation of antidepressants and depression care visits among Medicaid recipients. Psychiatr Serv 2010;61:386-91.
9. Mian AI. Depression in pregnancy and the postpartum period: Balancing adverse effects of untreated illness with treatment risks. J Psychiatr Pract 2005;11:389-96. (Pubitemid 41690418)
10. Einarson A, Choi J, Einarson TR, Koren G. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: Results from a large prospective database. J Obstet Gynaecol Can 2009;31:452-6.
11. Nakhai-Pour HR, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 2010;182:1031-7.
12. Santone G, Ricchi G, Rocchetti D, Tofani S, Bellantuono C. Is the exposure to antidepressant drugs in early pregnancy a risk factor for spontaneous abortion? A review of available evidences. Epidemiol Psichiatr Soc 2009;18:240-7.
13. Hale TW. Medication and mother' s milk, 13th edition. Amarillo, TX: Hale Publishing; 2008.
14. McNiel ME, Labbok MH, Abrahams SW. What are the risks associated with formula feeding? A re-analysis and review. Breastfeed Rev 2010;18:25-32.
15. Tuccori M, Montagnani S, Testi A, Ruggiero E, Mantarro S, Scollo C, et al. Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: An update. Postgrad Med 2010;122:49-65.
16. K ornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: Updated analysis. Clin Epidemiol 2010;2:29-36.
17. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data. Psychol Med 2010;40:1723-3.
18. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011;118:111-20.
19. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifi cally cardiac, defects: A meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88:159-70.
20. Einarson A, Koren G. First trimester exposure to paroxetine and prevalence of cardiac defects: Meta-analysis of the literature: Unfortunately incomplete. Birth Defects Res A Clin Mol Teratol 2010;88:588.
21. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: Population based cohort study. BMJ 2009;339:b3569. doi: 10.1136/bmj.b3569.
22. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di GE, et al. Paroxetine and fl uoxetine in pregnancy: A prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66:695-705.
23. Koren G. The effect of ascertainment bias in evaluating gestational antidepressant exposure. J Popul Ther Clin Pharmacol 2011;18:e174-5.
24. Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: Results of a large prospective cohort study. Can J Psychiatry 2009;54:242-6.
25. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83:68-76. (Pubitemid 351317794)
26. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM, National Birth Defects Prevention Study. Use of selective serotoninreuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-92. (Pubitemid 47001036)
27. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83. (Pubitemid 47001035)
28. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87. (Pubitemid 43209105)
29. Kallen B, Olausson PO. Maternal use of selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008;17:801-6.
30. Belik J. Fetal and neonatal effects of maternal drug treatment for depression. Semin Perinatol 2008;32:350-4.
31. Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009;18:246-52.
32. Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011;28:19-24.
33. Gentile S. On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: The prenatal antidepressant exposure syndrome. CNS Spectr 2010;15:167-85.
34. Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, Elliot R, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 2009;42:95-100.
35. Boucher N, Koren G, Beaulac-Baillargeon L. Maternal use of venlafaxine near term: Correlation between neonatal effects and plasma concentrations. Ther Drug Monit 2009;31:404-9.
36. Ter Horst PG, Jansman FG, van Lingen RA, Smit JP, de Jong-van den Berg LT, Brouwers JR. Pharmacological aspects of neonatal antidepressant withdrawal. Obstet Gynecol Surv 2008;63:267-79. (Pubitemid 351432767)
37. Kwon P, Lefkowitz W. Poor neonatal adaptation in term infant. Fluoxetine toxicity. Pediatr Ann 2008;37:131-3. (Pubitemid 351542953)
38. K oren G, Boucher N. Adverse effects in neonates exposed to SSRIs and SNRI in late gestation - Motherisk Update 2008. Can J Clin Pharmacol 2009;16:e66-7.
39. Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: A systematic review. Aust N Z J Psychiatry 2010;44: 978-96.
40. Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: A systematic review. J Affect Disord 2011;128:1-9.
41. Zahl PH, De LD, Ekeberg O, Hjelmeland H, Dieserud G. The relationship between sales of SSRI, TCA and suicide rates in the Nordic countries. BMC Psychiatry 2010;6:62.
42. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, et al. Use of antidepressant medications during pregnancy: A multisite study. Am J Obstet Gynecol 2008;198:194-5.
43. McManus P, Mant A, Mitchell PB, Montgomery WS, Marley J, Auland ME. Recent trends in the use of antidepressant drugs in Australia, 1990-1998. Med J Aust 2000;173:458-61.
44. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of effi cacy and tolerability. J Affect Disord 2000;58:19-36. (Pubitemid 30173208)
45. Exeter D, Robinson E, Wheeler A. Antidepressant dispensing trends in New Zealand between 2004 and 2007. Aust N Z J Psychiatry 2009;43:1131-40.
46. Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA. Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 2004;60:57-61. (Pubitemid 38471459)
47. Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: A review and clinical aspects. J Clin Psychopharmacol 2005;25:59-73. (Pubitemid 40129383)
48. Pariante CM, Seneviratne G, Howard L. Should we stop usingtricyclic antidepressants in pregnancy? Psychol Med 2011;41: 15-17.
49. Pearson KH, Nonacs RM, Viguera AC, Heller VL, Petrillo LF, Brandes M, et al. Birth outcomes following prenatal exposure to antidepressants. J Clin Psychiatry 2007;68:1284-9. (Pubitemid 47395633)
50. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007;16: 1086-94. (Pubitemid 350020061)
51. Westhuizen A,Van der. Antidepressants in Pregnancy. SA Pharmaceutical Journal 2010;77:10-18.
52. Preskorn SH. Tricyclic antidepressants: The whys and hows of therapeutic drug monitoring. J Clin Psychiatry 1989;50 Suppl: 34-42. (Pubitemid 19193458)
53. Deligiannidis KM. Therapeutic drug monitoring in pregnant and postpartum women: Recommendations for SSRIs, lamotrigine, and lithium. J Clin Psychiatry 2010;71:649-50.
54. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158:312-16. (Pubitemid 38451555)
55. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, et al. Child development following exposure to tricyclic antidepressants or fl uoxetine throughout fetal life: A prospective, controlled study. Am J Psychiatry 2002;159:1889-95. (Pubitemid 35283255)
56. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-62. (Pubitemid 27044627)
57. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: A preliminary report. Int J Psychiatry Med 1991;21:157-71.
58. Gracious BL , Wisner KL. Phenelzine use throughout pregnancy and the puerperium: Case report, review of the literature, and management recommendations. Depress Anxiety 1997;6:124-8. (Pubitemid 28079900)
59. Rybakowski JK. Moclobemide in pregnancy. Pharmacopsychiatry 2001;34:82-3. (Pubitemid 32221754)
60. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, et al. Pregnancy outcome following gestational exposure to venlafaxine: A multicenter prospective controlled study. Am J Psychiatry 2001;158:1728-30. (Pubitemid 32923672)
61. Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007;27:607-13. (Pubitemid 351339448)
62. Newport DJ, Ritchie JC, Knight BT, Glover BA, Zach EB, Stowe ZN. Venlafaxine in human breast milk and nursing infant plasma: Determination of exposure. J Clin Psychiatry 2009;70:1304-10.
63. Djulus J, Koren G, Einarson TR, Wilton L, Shakir S, Diav-Citrin O, et al. Exposure to mirtazapine during pregnancy: A prospective, comparative study of birth outcomes. J Clin Psychiatry 2006;67:1280-4. (Pubitemid 44439703)
64. Tonn P, Reuter SC, Hiemke C, Dahmen N. High mirtazapine plasma levels in infant after breast feeding: Case report and review of the literature. J Clin Psychopharmacol 2009;29:191-2.
65. Briggs GG, Ambrose PJ, Ilett KF, Hackett LP, Nageotte MP, Padilla G. Use of duloxetine in pregnancy and lactation. Ann Pharmacother 2009;43:1898-902.
66. Eyal R and Yaeger D. Poor neonatal adaptation after in utero exposure to duloxetine. Am J Psychiatry 2008;165:651. (Pubitemid 351705350)
67. Weinstein MR. The international register of lithium babies. Drug Inf J 1976;10:94-100.
68. Weinstein MR. Lithium in pregnancy. West J Med 1974;120:308.
69. Dodd S, Berk M. The safety of medications for the treatment of bipolar disorder during pregnancy and the puerperium. Curr Drug Saf 2006;1:25-33.
70. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. Areevaluation of risk of in utero exposure to lithium. JAMA 1994;271:146-50. (Pubitemid 24020593)
71. Yacobi S, Ornoy A. Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review. Isr J Psychiatry Relat Sci 2008;45:95-106.
72. The American Institute of Ultrasound, in Medicine. AIUM practice guideline for the performance of fetal echocardiography; 2010.
73. Yonkers KA, Wisner KL, Stowe Z, Leibenluft E, Cohen L, Miller L, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004;161:608-20. (Pubitemid 38445503)
74. Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during fi rst trimester. Lancet 1992;339:530-3.
75. Troyer WA, Pereira GR, Lannon RA, Belik J, Yoder MC. Association of maternal lithium exposure and premature delivery. J Perinatol 1993;13:123-27.
76. Ananth J. Side effects in the neonate from psychotropic agents excreted through breast-feeding. Am J Psychiatry 1978;135: 801-5. (Pubitemid 8371294)
77. Nars PW, Girard J. Lithium carbonate intake during pregnancy leading to large goiter in a premature infant. Am J Dis Child 1977;131:924-5. (Pubitemid 8165744)
78. Mizrahi EM, Hobbs JF, Goldsmith DI. Nephrogenic diabetes insipidus in transplacental lithium intoxication. J Pediatr 1979;94: 493-5. (Pubitemid 9111109)
79. Morrell P, Sutherland GR, Buamah PK, Oo M, Bain HH. Lithium toxicity in a neonate. Arch Dis Child 1983;58:539-41. (Pubitemid 13072481)
80. Filtenborg JA. Persistent pulmonary hypertension after lithium intoxication in the newborn. Eur J Pediatr 1982;138:321-3. (Pubitemid 12041561)
81. Davanzo R, Copertino M, De CA, Minen F, Amaddeo A. Antidepressant drugs and breastfeeding: A review of the literature. Breastfeed Med 2011;6:89-98.
82. Viguera AC, Newport DJ, Ritchie J, Stowe Z, Whitfi eld T, Mogielnicki J, et al. Lithium in breast milk and nursing infants: Clinical implications. Am J Psychiatry 2007;164:342-5.
83. Schou M. What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 1976;54:193-7.
84. Fink M, Taylor MA. Electroconvulsive therapy: Evidence and challenges. JAMA 2007;298:330-2.
85. Payne NA, Prudic J. Electroconvulsive therapy: Part I. A perspective on the evolution and current practice of ECT. J Psychiatr Pract 2009;15:346-68.
86. Rabheru K. The use of electroconvulsive therapy in special patient populations. Can J Psychiatry 2001;46:710-19. (Pubitemid 33127086)
87. Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994;45:444-50. (Pubitemid 24129371)
88. Anderson EL , Reti IM. ECT in pregnancy: A review of the literature from 1941 to 2007. Psychosom Med 2009;71:235-42.
89. M oya F, Kvisselgaard N. The placental transmission of succinylcholine. Anesthesiology 1961;22:1-6.
90. Spigset O. Anaesthetic agents and excretion in breast milk. Acta Anaesthesiol Scand 1994;38:94-103. (Pubitemid 24056663)
91. Nitsun M, Szokol JW, Saleh HJ, Murphy GS, Vender JS, Luong L, et al. Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk. Clin Pharmacol Ther 2006;79:549-57. (Pubitemid 43817944)
92. Andersen LW, Qvist T, Hertz J, Mogensen F. Concentrations of thiopentone in mature breast milk and colostrum following an induction dose. Acta Anaesthesiol Scand 1987;31:30-2. (Pubitemid 17228000)
93. Stuttmann R, Schafer C, Hilbert P, Meyer MR, Maurer HH. The breast feeding mother and xenon anaesthesia: Four case reports. Breast feeding and xenon anaesthesia. BMC Anesthesiol 2010;10:1.
94. Borgatta L, Jenny RW, Gruss L, Ong C, Barad D. Clinical signifi - cance of methohexital, meperidine, and diazepam in breast milk. JClin Pharmacol 1997;37:186-92. (Pubitemid 27163560)